LNK01001 not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
6 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Ankylosing Spondylitis
- Main trialPhase 3
- “The aim of this study is to evaluate the efficacy and safety of LNK01001 in subjects with active ankylosing spondylitis. The study is comprised of a 16-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 36-week open-label, long-term extension period (the Open-Label Extension Period). In the Double-Blind Period, participants will be randomized in a 1:1 ratio to receive either LNK01001 or placebo twice daily (BID). Participants in the placebo group will be switched to LNK01001 BID at Week 16 in the Open-Label Extension Period.”In the company’s words, NCT07237568 on ClinicalTrials.gov
Other drugs for Ankylosing Spondylitis
- JitongningTasly · Phase 3
- 6083SBio · Phase 3
- HS_SW01 cellsShenzhen Huishan Biotechnology Co., Ltd. · Phase 1/2
- VilamakitugXBiotech, Inc. · Phase 2
- HB0017Huahai Pharmaceutical (Huaota) · Phase 1
- Human Umbilical Cord Mesenchymal Stem CellsAsia Cell Therapeutics (Shanghai) Co., Ltd. · Phase 1
Coming up1
- NovPhase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT06276998
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Nov 2026 | A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis | |
| Phase 3Completed | 18 Apr 2025 | A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis. | |
| Phase 3Completed | 22 Aug 2025 | A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA) | |
| Phase 2Completed | 6 Dec 2022 | A Study of LNK01001 Capsule in Patients With Ankylosing Spondylitis | |
| Phase 2Completed | 29 Dec 2022 | A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis | |
| Phase 2Completed | 14 Jun 2023 | A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026